BioCentury
ARTICLE | Clinical News

OXi4503 combretastatin A1 di-phosphate: Preliminary Phase I data

January 21, 2013 8:00 AM UTC

Researchers at the University of Florida reported preliminary data from 5 patients with refractory AML in an open-label, dose-escalation, U.S. Phase I trial showing that IV OXi4503 produced an overall...